Liquidia (NASDAQ:LQDA) Director Sells $132,384.96 in Stock

Liquidia Corporation (NASDAQ:LQDA) Director Stephen Bloch sold 2,064 shares of the firm’s stock in a transaction that occurred on Friday, June 5th. The shares were sold at an average price of $64.14, for a total value of $132,384.96. Following the transaction, the director directly owned 1,785,242 shares of the company’s stock, valued at approximately $114,505,421.88. This trade represents a 0.12% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Liquidia Stock Up 1.9%

LQDA stock opened at $65.25 on Thursday. Liquidia Corporation has a twelve month low of $11.85 and a twelve month high of $66.78. The company has a quick ratio of 2.03, a current ratio of 2.22 and a debt-to-equity ratio of 1.18. The firm has a market cap of $5.80 billion, a PE ratio of 466.10 and a beta of 0.58. The business has a 50 day moving average of $48.50 and a 200 day moving average of $40.37.

Liquidia (NASDAQ:LQDA) last posted its quarterly earnings data on Monday, May 11th. The company reported $0.52 earnings per share for the quarter, beating analysts’ consensus estimates of $0.41 by $0.11. The company had revenue of $132.87 million during the quarter, compared to analyst estimates of $119.44 million. Liquidia had a return on equity of 46.82% and a net margin of 7.74%.The business’s revenue for the quarter was up 4187.1% on a year-over-year basis. On average, research analysts forecast that Liquidia Corporation will post 2.97 EPS for the current fiscal year.

Institutional Trading of Liquidia

Several large investors have recently modified their holdings of LQDA. Farallon Capital Management LLC grew its holdings in shares of Liquidia by 102.1% in the third quarter. Farallon Capital Management LLC now owns 8,565,638 shares of the company’s stock worth $194,783,000 after acquiring an additional 4,326,876 shares during the period. TCG Crossover Management LLC bought a new stake in shares of Liquidia in the third quarter worth $38,887,000. Caprock Group LLC bought a new stake in shares of Liquidia in the third quarter worth $37,114,000. MPM Bioimpact LLC grew its holdings in shares of Liquidia by 600.4% in the fourth quarter. MPM Bioimpact LLC now owns 1,400,869 shares of the company’s stock worth $48,316,000 after acquiring an additional 1,200,869 shares during the period. Finally, Voloridge Investment Management LLC bought a new stake in shares of Liquidia in the third quarter worth $12,571,000. Institutional investors own 64.54% of the company’s stock.

Analyst Ratings Changes

A number of analysts have commented on LQDA shares. BTIG Research lifted their target price on Liquidia from $50.00 to $59.00 and gave the stock a “buy” rating in a report on Monday, May 11th. HC Wainwright lifted their target price on Liquidia from $67.00 to $75.00 and gave the stock a “buy” rating in a report on Friday, June 5th. Wells Fargo & Company lifted their target price on Liquidia from $51.00 to $62.00 and gave the stock an “overweight” rating in a report on Tuesday, May 12th. Wall Street Zen raised Liquidia from a “buy” rating to a “strong-buy” rating in a report on Saturday, May 16th. Finally, Needham & Company LLC lifted their target price on Liquidia from $54.00 to $70.00 and gave the stock a “buy” rating in a report on Monday, May 11th. Three investment analysts have rated the stock with a Strong Buy rating, five have given a Buy rating and two have issued a Sell rating to the stock. According to data from MarketBeat, Liquidia currently has an average rating of “Moderate Buy” and a consensus price target of $60.29.

Liquidia Company Profile

Liquidia Technologies, Inc is a clinical-stage biopharmaceutical company headquartered in Research Triangle Park, North Carolina. The company leverages its proprietary PRINT® (Particle Replication In Non-wetting Templates) platform to engineer precisely shaped and sized drug particles, with the goal of improving delivery, efficacy and safety profiles. By controlling particle characteristics at the nanoscale, Liquidia seeks to enhance respiratory and other therapies that depend on targeted delivery.

The company’s lead product candidate, LIQ861, is a dry powder formulation of treprostinil designed for inhalation in patients with pulmonary arterial hypertension (PAH).